Osteoporotic Fracture Guidelines and Medical Education Related to the Clinical Practices: A Nationwide Survey in China

Jin Lu, MD¹, Zhong Ren, MSC², Xun Liu, MD³, You-jia Xu, MD, PhD⁴, Qiang Liu, MD, PhD⁵

¹Medical Affairs, Osteoporosis Franchise, Sandoz China, Tianjin, ²Medical Affairs, Osteoporosis Franchise, Sandoz China, Chengdu, ³Medical Affairs, Osteoporosis Franchise, Sandoz China, Shanghai, ⁴Orthopaedic Department, The 2nd Affiliate Hospital of Suzhou University, Suzhou and ⁵Orthopedic Department, Shanxi Da Yi Hospital, Taiyuan, China

Objectives: To investigate the knowledge and practices of Chinese doctors in the management of osteoporotic fractures after the Chinese osteoporotic fracture guidelines update and a series of medical education in 2017.

Methods: This was a cross-sectional survey of doctors in 71 cities across Mainland China. Based on the 2017 Chinese guidelines for the diagnosis and treatment of osteoporotic fractures, a questionnaire was designed and pre-tested for reliability and validity. Doctors were surveyed with the questionnaire after scientific meetings during February 2017 to January 2018 through WeChat or conference digital platforms or in paper form. Descriptive statistics was used to analyze the responses to the questionnaire.

Results: Overall, 314 valid questionnaires were confirmed. Regarding diagnosis, 77% agreed that osteoporosis could be diagnosed once an osteoporotic fracture occurred; 83% believed that the bone mineral density criteria for osteoporosis diagnosis would be T ≤ −2.5 SD. For treatment, almost all (99.7%) agreed with anti-osteoporosis treatment being one of the basic principles of osteoporotic fracture treatment; 71.6% considered bisphosphonates as the most commonly used anti-osteoporosis drug; 97% believed that patients who have used anti-osteoporosis drugs should reassess osteoporosis after osteoporotic fractures instead of discontinue; 95% thought that the patients who did not use anti-osteoporosis medications before osteoporotic fracture should be treated with anti-osteoporosis drugs after fracture treatment as early as possible; 89% agreed that the standard use of bisphosphonates after osteoporotic fracture would not affect bone healing adversely; 59% believed the course of bisphosphonates treatment for osteoporosis would be 3–5 years, and 27% considered it to be 1–3 years. The patient follow-up rate was poor: 46% selected follow-up rate <30%; only 20% selected follow-up rate >50%. Only 31% of the hospitals had long-term management programs for osteoporotic fractures.

Conclusions: Doctors generally adhered to the updated Chinese guidelines for osteoporotic fractures; frequent participation in medical education can help doctors to increase their awareness of osteoporosis as well as their acceptance and practice of the guidelines.

Key words: Chinese osteoporotic fracture guidelines; Medical education; Osteoporotic fracture; Questionnaire survey

Introduction

Osteoporosis is one of the most common skeletal diseases. It can occur at any age but is more common in postmenopausal women and older men¹. Severe osteoporosis will eventually lead to osteoporotic fractures. Approximately 40%–50% of females and 13%–22% of males sustain at least one osteoporotic fracture over the course of their entire life². Among the Chinese population, it is estimated that more than one-third of the women and approximately one-tenth of the men aged 50 years are expected to sustain a major osteoporotic fracture in their remaining lifetimes³. Osteoporotic fractures may happen at various sites of the body, and
fracture at some site, such as hip fracture, is associated with high mortality. In addition, the economic burden on patients and the healthcare system resulting from osteoporotic fractures is heavy. Osteoporotic fractures are also significantly associated with a higher risk of subsequent fracture and excess mortality. Therefore, prevention and treatment of osteoporotic fractures are particularly important.

To standardize the diagnosis and treatment of osteoporotic fractures, guidelines on osteoporosis and osteoporotic fractures have been developed in various countries; the Chinese osteoporotic fracture guidelines were first released in 2008 and was updated in 2017. However, the prevention and treatment of osteoporosis and osteoporotic fractures have not improved since the release of the guidelines. In a retrospective patient survey of Chinese women aged over 50 with fragility hip and vertebral fractures, osteoporosis was diagnosed in 56.8% of the patients, and 42.0% had never been assessed for bone mineral density. After the index fracture, 69.6% of the patients received supplements and/or anti-osteoporotic medications, among which only 39.6% received calcium with or without vitamin D supplementation. The reason for the low rates of diagnosis and treatment for osteoporosis after fracture may be various. The lack of awareness and knowledge of osteoporosis or osteoporotic fractures, which not only exists among the general population but also exists among medical staff, is an important reason.

Furthermore, multiple pathogenic factors are related to osteoporosis. In addition to the well-known factors such as gender, age, and calcium and vitamin D deficiency, diseases such as diabetes, rheumatoid arthritis, and gout are associated with osteoporotic fractures. Doctors in endocrinology departments are usually not aware of the necessity of anti-osteoporotic treatment for diabetic patients with a high risk of fragility fracture. Therefore, it is necessary to strengthen the education on osteoporosis and osteoporotic fractures for medical staff of the related specialties besides those specializing in osteoporosis or osteology.

To investigate the treatment given to osteoporotic fracture patients by orthopaedists at major hospitals in China, a nationwide survey among Chinese senior orthopaedists was conducted in 2014, and the results were published in 2016. As shown in that survey, there were quite a few orthopaedists lacking knowledge of treatment and management of osteoporotic fractures. Physicians with longer working experience tended to have better treatment knowledge and to manage osteoporotic conditions according to clinical practice guidelines. Following the Chinese osteoporotic fracture guidelines being updated and a series of medical training sessions and meetings having been held, we initiated a survey to investigate the current knowledge and practices of Chinese doctors from multiple specialties on management of osteoporotic fractures, and tried to find any factors that impact on the knowledge and clinical practice of the doctors.

Material and Methods

Design and Setting
This was a cross-sectional study conducted in Mainland China. Based on the 2017 Chinese guidelines for the diagnosis and treatment of osteoporotic fractures, a questionnaire containing 22 closed questions and an open question was developed covering the diagnosis and management of osteoporosis and osteoporotic fractures (Table 1). The 22 closed questions were categorized into several domains; the uncategorized open question (Q 22) asked which city the respondent worked in. A pre-test was taken to investigate the reliability and validity of the questionnaire before the survey began. The pre-test was conducted by 55 doctors from different cities. Each doctor was asked to respond to the questionnaire twice with an interval of 2–4 weeks to verify the consistency. Thirty-four valid questionnaires were finally collected. The Cronbach’s α measure was used to test internal consistency of the questionnaire items and good internal consistency was observed (Cronbach’s α > 0.7). The Kaiser–Meyer–Olkin measure of sampling adequacy and Bartlett’s test of sphericity showed that the results were suitable for factor analysis.

Participants
Doctors who were from departments related to bone or aged patients, such as orthopaedics, trauma, endocrine, rheumatism, geriatrics or osteoporosis, and who attended medical scientific meetings were eligible to participate in this survey (Table 2). There was no limit for sex, age, work experience, or job title.

Data Collection
Doctors were surveyed with the questionnaire during or after non-promotional medical scientific meetings held by Medical Affairs Sandoz China during February 2017 to January 2018 through WeChat or conference digital platforms or in paper form. Completed questionnaires were excluded if they had >10% missing data or essential information was missing.

Statistical Analysis
Descriptive analysis of the questionnaire data was performed using SPSS 20.0 software (SPSS, Chicago, IL, USA). Pearson’s χ²-test and percentages of the total were used for analysis. Additional sub-analysis by cohort based on the respondents’ job title and frequency of attending medical education was also performed.

Results
A total of 316 questionnaires were completed by participants from 24 provinces, including 71 cities across Mainland China. Of these, 314 (99%) responses (218 from WeChat, 72 in paper form, and 24 from conference digital platforms) were used for the analysis; another 2 responses were excluded due to the exclusion criteria.
| Question category                                      | Question number | Question content                                                                 | Question options                                      |
|-------------------------------------------------------|-----------------|----------------------------------------------------------------------------------|-------------------------------------------------------|
| Osteoporosis diagnosis                                | Q1              | Do you agree that osteoporosis can be diagnosed clinically by the occurrence of fragility fractures? | A. Agree  
B. Disagree  
C. Not sure |
|                                                       | Q2              | The bone mineral density criterion for osteoporosis diagnosis is:                 | A. $T \geq -1.0$ SD  
B. $-2.5 < T < -1.0$ SD  
C. $T \leq -2.5$ SD |
|                                                       | Q4              | The specific bone turnover biochemical markers recommended by the IOF are:       | A. P1NP, S-CTX  
B. Bone alkaline phosphatase, osteocalcin  
C. Vitamin D, calcium phosphate  
D. Thyroid hormone, parathyroid hormone |
| Characteristics and treatment principles of osteoporotic fractures | Q3              | Which descriptions of the characteristics of osteoporotic fracture are correct in your opinion? (Choose one or more) | A. Rapid bone loss will occur when a patient stays in bed after fracture, and will aggravate osteoporosis;  
B. Abnormal bone reconstruction, slow healing process, long recovery time, delayed fracture healing or even non-healing;  
C. Significantly increased risk of re-fracture at the same site or other sites;  
D. Low bone mass in the fracture site, poor bone quality, and most are comminuted fractures, which is difficult to achieve reduction;  
E. Poor stability of internal fixation treatment; internal fixation and implants are easy to loosen and escape, and the bone graft is easily absorbed;F. More common in the elderly who are with poor general condition and with other organ diseases or systemic diseases. Complications may occur during treatment and increase the complexity of treatment. |
|                                                       | Q5              | The basic principles of treatment of osteoporotic fractures are: (Choose one or more) | A. Reduction  
B. Fixation  
C. Functional exercise  
D. Anti-osteoporosis treatment |
|                                                       | Q6              | The common sites of osteoporotic fracture are: (Choose one or more)              | A. Spine  
B. Hip  
C. Distal radius  
D. Proximal humerus |
| Drug treatment                                         | Q7              | The dosages of calcium and vitamin D you usually give to patients in the early stage after osteoporotic fracture are: | A. Ca 400 mg/day, VitD 200 IU/d  
B. Ca 600 mg/day, VitD 400 IU/d  
C. Ca 1000 mg/day, VitD 800 IU/d  
D. Ca 1200 mg/day, VitD 800 IU/d  
E. Ca >1200 mg/day, VitD 1200 IU/d |
|                                                       | Q8              | Which type of anti-osteoporosis drug is the most prescribed in your clinical practice? (Choose one) | A. Bisphosphonates  
B. Selective estrogen receptor modulators, estrogens  
C. Calcitonin  
D. Anabolic agents  
E. Active vitamin D F. Chinese patent medicine |
|                                                       | Q9              | For patients who have used anti-osteoporosis drug, should the anti-osteoporosis drug be discontinued after osteoporotic fracture? | A. Yes  
B. Reassessing osteoporosis instead of blindly discontinuing the drug  
C. Unclear |
|                                                       | Q10             | Which is the optimal treatment for osteoporotic fracture patients who did not use anti-osteoporosis drugs before osteoporotic fracture? | A. Use anti-osteoporosis agents as soon as fracture treatment completed when the patient’s general condition is stable  
B. Start anti-osteoporosis medication after fracture healing  
C. Only basic supplement therapy with calcium and vitamin D  
D. Only use short-term calcitonin to suppress acute pain |
| Drug selection                                         | Q11             | Do you agree that standardized use of bisphosphonates after osteoporotic fractures would not adversely affect fracture healing? | A. Agree  
B. Disagree  
C. Not sure |
|                                                       | Q12             | Under what circumstances will you choose anabolic drugs to treat osteoporotic fractures? | A. For patients with osteoporotic fracture treated with anti-bone resorption drugs for many years  
B. For postmenopausal women who have osteoporotic |
TABLE 1 Continued

| Question category | Question number | Question content                                                                 | Question options                                                                 |
|-------------------|-----------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Medication time   | Q14             | Which do you think is the reasonable duration of bisphosphonates treatment for patients with osteoporosis? | A. <3 months  
B. 3–12 months (including 12 months)  
C. 1–3 years (including 3 years)  
D. 3–5 years  
E. Not sure |
| Patient management| Q15             | For osteoporosis patients after fracture healing, which department do you usually advise them to visit to continue anti-osteoporosis treatment? | A. Orthopaedics  
B. Endocrinology  
C. Rehabilitation  
D. Geriatrics  
E. Osteoporosis  
F. Rheumatology  
G. Chinese Medicine |
|                   | Q16             | What is the revisit and follow-up rate in patients with osteoporotic fracture in your clinical practice? | A. <30%  
B. 30%–50%  
C. >50% |
|                   | Q17             | Does your hospital have any system, personnel or program for long-term management of osteoporotic fractures? | A. Yes  
B. No  
C. Under arrangement |
| Feedback of respondents | Q18         | Are you satisfied with the content and discussion of this meeting? Please provide your valuable comments and suggestions. | A. Satisfied  
B. Fair  
C. Unsatisfied |
|                   | Q19             | What is your expertise?                                                            | A. Spine  
B. Joint  
C. Trauma  
D. General orthopaedics and others  
E. Endocrine  
F. Rheumatism  
G. Geriatrics  
H. Osteoporosis  
I. General internal medicine and others |
|                   | Q20             | What is your job title?                                                             | A. Chief physician  
B. Deputy chief physician  
C. Attending physician  
D. Resident physician |
|                   | Q21             | What is the grade of your hospital?                                                | A. Tertiary hospital  
B. Secondary hospital  
C. Primary hospital |
|                   | Q23             | How many times have you attended osteoporosis-related training or meetings in the past year? | A. <3 times  
B. 3–7 times  
C. >7 times |

Characteristics of Respondents
The characteristics of the respondents are shown in Table 2. Among the 314 respondents, 63 (20%) were chief physicians, 92 (29%) were deputy chief physicians, 110 (35%) were attending physicians, and 49 (16%) were resident physicians. The majority specialized in spine (101, 32%), endocrine (59, 19%), rheumatism (44, 14%), joints (35, 11%), or osteoporosis (13, 4%). Most (260, 83%) of them were from tertiary hospitals. Nearly half (161, 51%) of the doctors had attended osteoporosis-related training or meetings in the past year fewer than three times, and 30 (10%) respondents had attended training or meetings more than seven times.

Diagnosis of Osteoporosis
In response to the question “Do you agree that osteoporosis can be diagnosed clinically by the occurrence of fragility fractures?” most (77%) of the respondents chose “agree”; 15% disagreed and 8% were not sure. Sub-group analysis showed
that the percentage of respondents who chose "agree" increased with the frequency of attending medical education: 70%, 82%, and 87% in groups of <3 times, 3–7 times, and >7 times respectively. When analyzed according to job title, the percentage of respondents answering yes was 59%, 77%, 82% and 83% among resident physician, attending physician, deputy chief physician and chief physician groups, respectively (Fig. 1).

Eighty-three percent of the respondents believed that the bone mineral density criteria for osteoporosis diagnosis would be $T \leq -2.5$ standard deviation (SD), and 15% believed it should be $-2.5 < T < -1.0$. Seventy-five percent thought procollagen type I N-terminal propeptide (P1NP) and collagen type I crosslinked C-telopeptide (S-CTX) should be the specific bone turnover biochemical markers recommended by the International Osteoporosis Foundation.

**Characteristics and Treatment Principles of Osteoprotic Fractures**

With regard to the characteristics of osteoporotic fractures (Q3), the majority of respondents had good awareness; the selection percentage of option A, B, C, D, E, and F was 96%, 93%, 93%, 89%, 90%, and 91%, respectively. Almost all (99.7%) agreed that anti-osteoporosis treatment should be one of the basic principles of osteoporotic fracture treatment; the percentage of respondents who picked “reduction,” “fixation,” and “functional exercise” was 87%, 88%, and 90% respectively. The rates of respondents regarding the spine and hip as the most common sites of osteoporotic fractures were 97% and 92%, respectively, while the rates of those choosing distal radius and proximal humerus were 83% and 67%, respectively.

**Drug Treatment**

Among the respondents, 52% recommended that the daily dosage of calcium and vitamin D early after osteoporotic fractures should be 1000 mg and 800 IU, respectively; 20% thought the daily dosage should be 1200 mg and 800 IU, respectively (Fig. 2). There was no significant difference in the distribution of options among groups, and it did not correlate with the frequency of attending medical education or the job title of respondents.

Among the respondents, 71.6% considered bisphosphonates as the most commonly used anti-osteoporosis drug; active vitamin D was the second most...
frequently used drug (Fig. 3). Ninety-seven percent believed that patients who have used anti-osteoporosis drugs should reassess osteoporosis after osteoporotic fracture instead of discontinuing; 95% agreed that the patients who did not use anti-osteoporosis medications before osteoporotic fracture should be treated with anti-osteoporosis drugs as soon as fracture treatment was completed (Fig. 4A).

Drug Selection, Medication Time, and Duration
Most (89%) of the respondents agreed that standardized use of bisphosphonates after osteoporotic fractures would not adversely affect fracture healing. For the question on the application scenarios of anabolic drugs, 63% would use this kind of drug for patients with osteoporotic fractures treated with anti-bone resorption drugs for many years, and 26% would use it many times for postmenopausal women who have osteoporotic vertebral fractures or hip fractures.

Regarding the effects of bisphosphonates on fracture healing and internal implants (Q13), most of the respondents agreed on their positive effects (81%, 90%, and 86% for options A, B, and C, respectively). Regarding the duration of bisphosphonates treatment, 59% of the respondents suggested the reasonable duration for osteoporosis treatment should be 3–5 years, and the option of 1–3 years was chosen by 27% of the respondents. With the frequency of medical education increased, more respondents agreed that the duration of bisphosphonates treatment should be 3–5 years, as recommended by the guidelines, and fewer respondents would prescribe for less than 1 year. Meanwhile, more respondents in the chief physician and deputy chief physician group agreed on 3–5 years compared with the group of attending physicians and resident physicians (Fig. 5).

Patient Management
For subsequent therapy after fracture healing, 37% and 38% of the respondents suggested the patients visit orthopaedics and osteoporosis departments, respectively, and 16% recommended visiting an endocrinology department. Thirty-one percent of the hospitals the respondents were working in had long-term management programs for osteoporotic fractures, while 37% had no related program and the other 32% had programs at planning or preparatory stage. With respect to patient follow-up, nearly half (46%) of the respondents had a follow-up rate of <30%, and 20% had a rate of >50%. A larger percentage of respondents in the group attending medical education >7 times had a patient follow-up rate >50% compared with the groups attending medical education 3–7 times and <3 times (37%, 15% and 20%, respectively). The chief physician group had the largest percentage (27%) of patient follow-up rate >50%. The patient follow-up rate was higher in hospitals having long-term management programs for

Fig. 2 The most prescribed daily dosages of calcium and vitamin D.

Fig. 3 The most prescribed anti-osteoporosis drugs.

Fig. 4 A: The knowledge on timing of anti-osteooporosis medication.

Fig. 4 B: If anti-osteoporosis drugs should be used peri-operatively.
osteoporotic fractures than in hospitals with no related program or with programs at planning or preparatory stage (Fig. 6).

**Discussion**

Osteoporosis-related fractures are a worldwide public health problem. With the increase in the elderly population, more and more osteoporosis and osteoporotic fracture patients will emerge. The level of knowledge of medical staff has important impacts on disease management. Prior studies in China have shown that although most orthopaedic doctors are aware of the necessity of anti-osteoporosis therapy for osteoporotic fractures, more effort should be made to improve their knowledge on disease screening, diagnosis, and treatment19,20. In this survey we investigated the knowledge of doctors in multiple related specialties following updates of the guidelines and increased medical education.

With regard to the dosage of calcium and vitamin D, approximately half of the respondents would prescribe 1000 mg/day for calcium and 800 IU/day for vitamin D, as recommended in the updated guidelines, compared with 32% choosing 1000 mg/day for calcium and 49.6% choosing 800 IU/day for vitamin D in the 2016 survey. There was no obvious difference in the distribution of options between overall and sub-group analysis, and it was not related to the frequency of attending medical education or job title. This could be explained by several possible reasons, including: it was not emphasized enough on this topic during medical training or meetings; the accustomed prescription had been able to meet the treatment needs for patients; and there may also be geographical differences.

Compared with the survey published in 2016, more respondents agreed that standardized bisphosphonates therapy has no adverse effect on fracture healing after osteoporotic fractures (89% vs 29.3%) (Fig. 7). The majority (95%) of respondents in this survey agreed to use anti-osteoporosis drugs as soon as possible after fracture treatment when the patients’ general condition was stable, whereas 76% in the 2016 survey agreed to use anti-osteoporosis drugs during the perioperative period (Fig. 4). More respondents in this survey suggested 3–5 years, as the guidelines recommended, would be the reasonable duration for bisphosphonates treatment compared to 2016 (59% vs 29%) (Fig. 8). Sub-analysis showed the percentage of respondents who agreed that the recommended duration of
The influence of the doctors’ job title on the patient follow-up rate may be more due to the patient’s trust in high-ranking physicians. It is worth mentioning that the patient follow-up rates of respondents from hospitals with long-term management programs for osteoporotic fractures were much higher, suggesting that long-term programs for osteoporotic fracture management in hospitals are critical for follow-up visits and patient compliance. For example, a fracture liaison service, such as that launched by the International Osteoporosis Foundation in 2012, can improve patient adherence and was proved to be an effective model of care for patients with osteoporotic fractures.

Through comparison of the results of the survey published in 2016, we found that the awareness and the level of diagnosis and treatment of osteoporosis of doctors have been improved. The diagnosis and treatment of osteoporosis and long-term management of osteoporotic fractures should be based on doctors’ knowledge and patient compliance. We believe that such results are meaningful; they are also helpful for government and enterprises to develop policies and strategies on osteoporosis management. Meanwhile, we call for strengthening medical education for both medical staff and the general population to prevent osteoporosis and reduce fracture incidence.

This questionnaire survey was conducted mainly through WeChat and online methods, which improved the rate of valid questionnaires and avoided interference caused by human factors in the face-to-face questionnaire form. However, as this was a cross-sectional survey with treatment data retrieved from doctors’ subjective clinical concepts instead of clinical records, personal biases may exist and affect the results.

Conclusions
The results of this survey demonstrated that doctors knowledge about osteoporosis and osteoporotic fractures improved in relation to diagnosis, bisphosphonates and bone healing, timing of medication and long-term treatment, and generally adhered to the updated Chinese guidelines for osteoporotic fractures. Frequent medical education can help doctors to enhance the awareness of osteoporosis and osteoporotic fractures as well as the acceptance and practice of guidelines. Long-term management programs for osteoporotic fractures in hospitals may be useful for improving patient compliance and optimizing disease management.

Acknowledgments
We acknowledge the support from the Medical Science Liaison team, Medical Affairs, Sandoz China in the collection of survey data. Medical writing assistance was provided by CICA (Shanghai, China).

References
1. Akkawi I, Zmerly H. Osteoporosis: current concepts. Joints, 2018, 6: 122–127.
2. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int, 2005, 16: S3–S7.
3. Si L, Winzenberg TM, Chen M, Jiang Q, Palmer AJ. Residual lifetime and 10 year absolute risks of osteoporotic fractures in Chinese men and women. Curr Med Res Opin, 2015, 31: 1149–1156.
4. Chow SK, Qin JH, Wong RM, et al. One-year mortality in displaced intracapsular hip fractures and associated risk: a report of Chinese-based fragility fracture registry. J Orthop Surg Res, 2018, 13: 235.

5. Liu R, Chao A, Wang K, Wu J. Incidence and risk factors of medical complications and direct medical costs after osteoporotic fracture among patients in China. Arch Osteoporos, 2018, 13: 12.

6. Black DM, Cauley JA, Wagman R, et al. The ability of a single BMD and fracture history assessment to predict fracture over 25 years in postmenopausal women: the study of osteoporotic fractures. J Bone Miner Res, 2018, 33: 389–395.

7. Wasnich RD, Davis JW, Ross PD. Spine fracture risk is predicted by non-spine fractures. Osteoporos Int, 1994, 4: 1–5.

8. Wang O, Hu Y, Gong S, et al. A survey of outcomes and management of patients post fragility fractures in China. Osteoporos Int, 2015, 26: 2631–2640.

9. Wang CY, Fu SH, Huang CC, Hung CC, Yang RS, Hsiao FY. Visualisation of the unmet treatment need of osteoporotic fracture in Taiwan: a nationwide cohort study. Int J Clin Pract, 2018, 72: e13246.

10. Wilk A, Sajjan S, Modi A, Fan CPS, Mavros P. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA. Osteoporos Int, 2014, 25: 2777–2786.

11. Castel H, Bonneh DY, Sherf M, Liel Y. Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures. Osteoporos Int, 2001, 12: 559–564.

12. Fogelman Y, Goldshein I, Esh-Shalom S. Managing osteoporosis: a survey of knowledge, attitudes and practices among primary care physicians in Israel. PLoS One, 2016, 11: e0160661.

13. Chami G, Jeys L, Freudmann M, Connor L, Siddiqi M. Are osteoporotic fractures being adequately investigated? A questionnaire of GP & orthopaedic surgeons. BMC Fam Pract, 2006, 7: 7.

14. Wang XF, Yu JJ, Wang XJ, et al. The associations between hypovitaminosis D, higher PTH levels with bone mineral densities, and risk of the 10-year probability of major osteoporotic fractures in Chinese patients with T2DM. Endocr Pract, 2018, 24: 334–341.

15. Phuan-Udom R, Lektrakul N, Katchamart W. The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis. Clin Rheumatol, 2018, 37: 2603–2610.

16. Wang Y, Zhou R, Zhong W, Hu C, Lu S, Chai Y. Association of gout with osteoporotic fractures. Int Orthop, 2018, 42: 2041–2047.

17. Man Y, Pan W, Lu J, et al. Treatment and management of osteoporotic fractures: a nation-wide survey of 484 senior orthopaedists in China. Orthop Surg, 2016, 8: 432–439.

18. Osteoporosis Group of Chinese Society of Orthopedics. Guideline on diagnosis and treatment of osteoporotic fractures. Chin J Orthop, 2017, 37: 1–10.

19. Yu SF, Guo JZ, Wu B, Zhang C, Chen W, Chen Y. Questionnaire survey on osteoporosis diagnosis and treatment among orthopedic surgeons in tertiary hospitals. Chin J Joint Surg (Electronic Edition), 2013, 7: 93–95.

20. He L, Zhong W, Li N. Do orthopaedic surgeons regard the treatment and prevention of osteoporotic fractures? J Pract Orthop, 2009, 15: 241–244.

21. Morell S, Hemmeler C, Amsler F, Gross T. Adherence to osteoporosis pharmacotherapy one year after osteoporotic fracture - a Swiss trauma center secondary prevention project. Swiss Med Wkly, 2017, 147: w14451.

22. Klop C, Welsing PM, Elders PJ, et al. Long-term persistence with anti- osteoporosis drugs after fracture. Osteoporos Int, 2015, 26: 1831–1840.

23. Luc M, Corriveau H, Boire G, Filiatraut J, Beaulieu MC, Gaboury I. Patient-related factors associated with adherence to recommendations made by a fracture liaison service: a mixed-method prospective study. Int J Environ Res Public Health, 2018, 15: 944.